Anugerah 88 Logo
$1.04-0.02|(-1.43%)
52W H: 1.9552W L: 1.02Beta: 1.34

About Pliant Therapeutics Inc

Frequently Asked Questions

What is the 52-week range for PLRX?

The 52-week high is $1.95 and the 52-week low is $1.02.

What is the P/E ratio for PLRX?

The P/E ratio data is currently unavailable.

What is the dividend yield for PLRX?

This company does not currently pay a dividend or the data is unavailable.

What is the Return on Equity (ROE)?

The trailing twelve months (TTM) Return on Equity is -69.56%.

What is the Net Profit Margin?

The Net Profit Margin (TTM) is -2871.17%.

What is the Price to Book (P/B) Ratio?

The annual Price to Book ratio stands at 0.41.

Analyst Recommendation Trends

Wall Street analyst consensus for PLRX over the last few months:

2026-09-01
Buy: 0
S.Buy: 0
Hold: 6
Sell: 2
2026-08-01
Buy: 0
S.Buy: 0
Hold: 6
Sell: 2
2026-07-01
Buy: 0
S.Buy: 0
Hold: 6
Sell: 2
2026-06-01
Buy: 1
S.Buy: 0
Hold: 6
Sell: 2

Latest PLRX News

Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer

Leader in targeted immuno-oncology drug development brings three decades of academic and biopharmaceutical oncology expertise SOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced the appointment of David Raben, M.D., as Chief Medical Officer. Dr. Raben brings more than 30 years of experience in academic translational

Yahoo9/30/2026

Related Stocks (Peers)

Companies operating in similar sectors to PLRX:

NTHIVRCATELORFLCINGPLRXELOXTLPHHYPDPLTH.CNODTCLLY

Recent Insider Transactions

DateNameShares ChangedPriceValue
2026-10-01Raben David+575,000--
2026-07-09Borellini Flavia+60,000--
2026-07-09Iannone Robert+60,000--
2026-06-11Krognes Steve E.+70,000--
2026-06-11Cline Darren S+70,000--
2026-06-11Curnutte John T+70,000--
2026-06-11MCCOURT Thomas A+70,000--
2026-06-11Huh Hoyoung+70,000--
2026-06-11CROWELL GAYLE A+70,000--
2026-04-17Kuo Minnie+55,200--
2026-04-17Kuo Minnie-55,200--
2026-04-17Kuo Minnie+40,000--
2026-04-17Kuo Minnie-40,000--
2026-04-17Kuo Minnie+150,000--
2026-04-17Kuo Minnie-150,000--
2026-04-17Cummings Keith Lamont+113,300--
2026-04-17Cummings Keith Lamont-113,300--
2026-04-17Cummings Keith Lamont+110,500--
2026-04-17Cummings Keith Lamont-110,500--
2026-04-17Cummings Keith Lamont+76,200--
2026-04-17Cummings Keith Lamont-76,200--
2026-04-17Cummings Keith Lamont+124,000--
2026-04-17Cummings Keith Lamont-124,000--
2026-04-17Cummings Keith Lamont+74,250--
2026-04-17Cummings Keith Lamont-74,250--
2026-04-17Cummings Keith Lamont+18,198--
2026-04-17Cummings Keith Lamont-18,198--
2026-04-17Cummings Keith Lamont+76,047--
2026-04-17Cummings Keith Lamont-76,047--
2026-04-17Coulie Bernard+325,000--
2026-04-17Coulie Bernard-325,000--
2026-04-17Coulie Bernard+256,300--
2026-04-17Coulie Bernard-256,300--
2026-04-17Coulie Bernard+206,300--
2026-04-17Coulie Bernard-206,300--
2026-04-17Coulie Bernard+440,000--
2026-04-17Coulie Bernard-440,000--
2026-04-17Coulie Bernard+250,000--
2026-04-17Coulie Bernard-250,000--
2026-04-17Coulie Bernard+327,262--
2026-04-17Coulie Bernard-327,262--
2026-04-17Coulie Bernard+146,841--
2026-04-17Coulie Bernard-146,841--
2026-04-17Cheung Lily+51,750--
2026-04-17Cheung Lily-51,750--
2026-04-17Cheung Lily+52,000--
2026-04-17Cheung Lily-52,000--
2026-04-17Cheung Lily+123,000--
2026-04-17Cheung Lily-123,000--
2026-01-22Cummings Keith Lamont+400,000--
2026-01-22Kuo Minnie+300,000--
2026-01-22Cheung Lily+300,000--
2026-01-22Coulie Bernard+1,230,000--
2026-01-20Cummings Keith Lamont-24,002$1.28$30,723
2026-01-20Cheung Lily-7,534$1.28$9,644
2026-01-20Coulie Bernard-89,375$1.28$114,400
2026-01-20Kuo Minnie-6,917$1.28$8,854